Genetic assessments of breast cancer risk that do not account for polygenic background are incomplete and lead to incorrect preventative strategies
Preprint
Abstract
Breast cancer is the most common cancer among women and is a leading cause of cancer mortality worldwide. There is a significant genetic component to breast cancer risk which is the result of both rare pathogenic mutations and common genome-wide variation. However, the penetrance of pathogenic mutations varies widely and their frequency is low, both at a population level and amongst breast cancer cases. Polygenic risk scores, which aggregate the effect of hundreds to millions of common genome-wide variants offer a way to further understand the contribution of genetics to disease risk. Here we analyse genome-wide data from 221,479 women and 90,307 high coverage exomes to understand how rare and common variation affect lifetime breast cancer risk. We show that PRS strongly modulates the penetrance of mutations in 8 breast cancer susceptibility genes. For example, lifetime risk in BRCA1 carriers with low polygenic risk is almost one third that of carriers with high PRS (26% v 69% in the bottom and top PRS deciles, respectively). Adding family history of breast cancer provides additional stratification on the potential outcome of disease in carriers of rare mutations. PRS also identifies a significant fraction of the population at equivalent risk to carriers of moderate impact pathogenic variants and who are an order of magnitude more common at a population level. These results have important implications for breast cancer risk mitigation strategies, indicating that the genetic risk of breast cancer is determined by both monogenic mutation and polygenic background, and that assessments of genetic risk for breast cancer risk that do not consider the polygenic background are imprecise and unreliable.Keywords
This publication has 32 references indexed in Scilit:
- Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk ScoreJournal of Clinical Oncology, 2021
- CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than CheckmateCells, 2020
- Identifying breast cancer susceptibility genes – a review of the genetic background in familial breast cancerActa Oncologica, 2019
- Gene-Panel Sequencing and the Prediction of Breast-Cancer RiskNew England Journal of Medicine, 2015
- Breast-Cancer Risk in Families with Mutations in PALB2New England Journal of Medicine, 2014
- Genetic susceptibility to breast cancerMolecular Oncology, 2010
- Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the familyBMC Cancer, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- ATM and breast cancer susceptibilityOncogene, 2006
- Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the diseaseThe Lancet, 2001